China Pharma Holdings (CPHI) Return on Sales (2016 - 2025)
China Pharma Holdings' Return on Sales history spans 16 years, with the latest figure at 1.0% for Q4 2025.
- For Q4 2025, Return on Sales rose 8.0% year-over-year to 1.0%; the TTM value through Dec 2025 reached 0.77%, up 28.0%, while the annual FY2025 figure was 0.77%, 28.0% up from the prior year.
- Return on Sales reached 1.0% in Q4 2025 per CPHI's latest filing, down from 0.86% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.24% in Q1 2023 to a low of 1.55% in Q2 2024.
- Average Return on Sales over 5 years is 0.63%, with a median of 0.55% recorded in 2022.
- Peak YoY movement for Return on Sales: crashed -101bps in 2024, then skyrocketed 104bps in 2025.
- A 5-year view of Return on Sales shows it stood at 0.34% in 2021, then decreased by -28bps to 0.43% in 2022, then plummeted by -32bps to 0.57% in 2023, then crashed by -88bps to 1.08% in 2024, then grew by 8bps to 1.0% in 2025.
- Per Business Quant, the three most recent readings for CPHI's Return on Sales are 1.0% (Q4 2025), 0.86% (Q3 2025), and 0.52% (Q2 2025).